Shares of Dendreon traded down 7.01% during mid-day trading on Tuesday, hitting $7.16. Dendreon has a one year low of $6.46 and a one year high of $43.96. The company’s market cap is $1.058 billion.
Several other analysts have also recently commented on the stock. Analysts at Maxim Group initiated coverage on shares of Dendreon in a research note to investors on Friday, May 18th. They set a “sell” rating and a $5.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Dendreon in a research note to investors on Wednesday, May 9th. They now have a $9.25 price target on the stock. Finally, analysts at Credit Suisse (NYSE: CS) raised their EPS on shares of Dendreon in a research note to investors on Tuesday, May 8th. They now have a “neutral” rating and a $12.00 price target on the stock.
Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients.